The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TRX | -86.57% | -80.41% | -27.82% | -99% |
| S&P | +16.23% | +94.45% | +14.22% | +547% |
Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. It operates through the BioSurgery, Orthopaedics & Dental, Cardiac and Other divisions. Its patented decellularisation technology removes DNA and other cellular material from animal and human tissue leaving a cellular tissue scaffold, which is not rejected by the patient's body and can then be used to repair diseased and worn out body parts. The company was founded by Eileen Ingham and John Fisher in May 2006 and is headquartered in Leeds, the United Kingdom.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
